The agenda includes:
Preparation of positions on the legitimacy of qualifying health care services as guaranteed benefits:
- Percutaneous thermoablation using radiofrequency current (RFA) or microwaves (MWA) under the guidance of computed tomography for the indication primary malignant neoplasm of main bronchus (ICD-10: C34.0, C34.1, C34.2, C34.3, C34.8, C34.9), secondary malignant neoplasm of main bronchus (ICD-10: C78.0);
- Percutaneous thermoablation using radiofrequency current (RFA) or microwaves (MWA) under the guidance of computed tomography or magnetic resonance imaging for the indication secondary malignant neoplasm of main bone (ICD-10: C79.5), osteosarcoma (ICD-10: D16.1, D16.2, D16.3, D16.4, D16.5, D16.6, D16.7, D16.8, D16.9), primary malignant neoplasm of bone (ICD-10: C40, C41);
- Percutaneous thermoablation using radiofrequency current (RFA) or microwaves (MWA) under the guidance of computed tomography or magnetic resonance imaging or X-ray fluoroscopy with cementoplasty the indication secondary malignant neoplasm of bone (ICD-10: C79.5), osteosarcoma (ICD-10: D16.1, D16.2, D16.3, D16.2, D16.3, D16.4, D16.5, D16.6, D16.7, D16.8, D16.9), primary malignant neoplasm of bone (ICD-10: C40, C41);
- Percutaneous thermoablation using radiofrequency current (RFA) or microwaves (MWA) under the guidance of computed tomography for the indication neoplasm of the adrenal glands (ICD-10: C74, C79.7, D35.0);
- Percutaneous cryoablation under the guidance of computed tomography or magnetic resonance imaging for the indication secondary malignant neoplasm of bone (ICD-10: C79.5);
- Percutaneous cryoablation under the guidance of computed tomography or magnetic resonance imaging with cementoplasty for the indication secondary malignant neoplasm of bone (ICD-10: C79.5);
- Percutaneous cryoablation under the guidance of computed tomography for the indication malignant neoplasm of chest (ICD-10: C34, C38, C78.0, C78.1, C78.2).
Preparation of positions on the evaluation of drugs:
- Sarclisa (isatuximab) under the drug programme “Treatment of patients with plasmocytic myeloma (ICD-10: C90.0)” in combination with pomalidomide and dexamethasone,
- Jyseleca (filgotinib) under the drug programme B.33. “Treatment of patients with active rheumatoid arthritis and juvenile idiopathic arthritis (ICD-10: M05, M06, M08)”,
- Evrenzo (roxadustat) under the drug programme B.37. “Treatment of anaemia in chronic renal failure (ICD-10 N 18)”.
Preparation of a position on the legitimacy of granting reimbursement approval for the medicinal products: Reducto spezial (potassium dihydrogen phosphate, sodium monohydrogen phosphate dihydrate) for the indication: hypophosphatemic rickets.
Preparing opinions on draft health policy programmes of local government units:
- “Health policy programne of the Municipality of Kleszczów for the period 2023-2025 in the scope of prevention of dental and oral diseases”,
- “Health policy programme in the area of mandatory and recommended vaccinations with ‘6-i-1’ combined vaccine” (Municipality og Kleszczów).
- “Slupsk programme to counteract the effects of infertility by subsidising IVF treatment for the period 2023-2027”.
Preparation of an opinion on the inclusion in the reimbursement of medicines containing the active substance anakinra for indications: other congenital autoinflammatory syndromes: TRAPS, FMF after failure of treatment with the maximum tolerated dose of colchicine; IL1-mediated polygenic autoinflammatory syndromes: – Schnitzler syndrome; secondary amyloidosis, dependent on autoinflammatory lesions.